PMID- 27647398
OWN - NLM
STAT- MEDLINE
DCOM- 20170517
LR  - 20181202
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 38
IP  - 9
DP  - 2016 Sep 23
TI  - [HER-2 expression and clinical significance in esophagogastric junction 
      adenocarcinoma (Siewert type Ⅱ)].
PG  - 667-71
LID - 10.3760/cma.j.issn.0253-3766.2016.09.006 [doi]
AB  - OBJECTIVE: To investigate the human epidermal growth factor receptor-2 (HER-2) 
      expression in esophagogastirc junction adenocarcinoma(Siewert type Ⅱ)and its 
      clinical significance. METHODS: A total of 180 patients with esophagogastric 
      junction adenocarcinoma (Siewert type Ⅱ) were included in this study. The HER-2 
      expression was detected by immunohistochemistry (IHC), and fluorescence in situ 
      hybridization (FISH) analysis was performed to assess the HER-2 gene 
      amplification in the IHC-positive and IHC-weak positive cases. RESULTS: HER-2 
      overexpression (3+ ), weak positive (2+ ) and negative (1+ /0) was 11.7%(21/180), 
      8.9%(16/180), and 79.4%(143/180), respectively. The FISH analysis showed HER-2 
      gene amplification in 95.2%(20/21) of HER-2(3+ ) cases and 18.8% (3/16) of 
      HER-2(2+ ) cases. The concordance rate between IHC and FISH was 95.2%. 
      Overexpression of HER-2(3+ ) was associated with the tumor differentiation 
      (P<0.05), and irrelevant to age, sex, pT stage, pN stage, pM stage and pTNM stage 
      (P>0.05). The median overall survival time (OS) was 13 months in HER-2(3+ ) 
      patients, significantly shorter than the 21 months in HER-2(2+ ) and HER-2(+ /-) 
      cases (P<0.01). CONCLUSIONS: Approximately 11.7% of the patients with 
      esophagogastric junction adenocarcinoma (Siewert type Ⅱ) are HER-2-positive on 
      IHC. HER-2 overexpression is associated with the tumor differentiation. IHC can 
      be used as a screening test for the positive expression of HER-2 in the 
      esophagogastirc junction adenocarcinoma (Siewert type Ⅱ). However, FISH detection 
      can be used as a more reliable detection method.
FAU - Luo, Z L
AU  - Luo ZL
AD  - Department of Cardiothoracic Surgery, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong 637000, China.
FAU - Fu, M Y
AU  - Fu MY
AD  - Department of Cardiothoracic Surgery, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong 637000, China.
FAU - Tian, D
AU  - Tian D
AD  - Department of Cardiothoracic Surgery, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong 637000, China.
FAU - Shi, G D
AU  - Shi GD
AD  - Department of Cardiothoracic Surgery, Affiliated Hospital of North Sichuan 
      Medical College, Nanchong 637000, China.
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Adenocarcinoma
MH  - *Esophageal Neoplasms
MH  - *Esophagogastric Junction
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2
MH  - *Stomach Neoplasms
EDAT- 2016/09/21 06:00
MHDA- 2017/05/18 06:00
CRDT- 2016/09/21 06:00
PHST- 2016/09/21 06:00 [entrez]
PHST- 2016/09/21 06:00 [pubmed]
PHST- 2017/05/18 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3766.2016.09.006 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2016 Sep 23;38(9):667-71. doi: 
      10.3760/cma.j.issn.0253-3766.2016.09.006.